AP-1 activation mediates post-natal cardiomyocyte maturation
Cardiovascular Research · 2023
DOI: 10.1093/cvr/cvac088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Hongjie Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai Key Laborato…. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Transcription Factor AP-1. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Key Research and Development Program, Ministry of Science and Technology of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Post-natal maturation of mammalian cardiomyocytes proceeds rapidly after birth, with most of the myocytes exiting cell cycle, becoming binucleated, and adopting oxidative phosphorylation as the primary metabolic route. The triggers and transcriptional programmes regulating cardiomyocyte maturation have not been fully understood yet. We performed single-cell RNA-Seq in post-natal rat hearts in order to identify the important factors for this process. Methods and results Single-cell RNA-Seq profiling was performed of post-natal Day 1 and Day 7 rat hearts, and we found that members of the activating protein 1 (AP-1) transcription factors showed a transient up-regulation in the maturing cardiomyocytes, suggesting their functional involvement in the process. Activating members of the AP-1 family by palmitate or adrenergic stimulation inhibited cardiomyocyte cytokinesis and promoted cardiomyocyte maturation. In contrast, knocking down AP-1 members Atf3 and Jun promoted cardiomyocyte cytokinesis, reduced polyploidy, and inhibited maturation. Mechanistically, RNA-Seq results and rescue experiments indicated that AP-1 members activate the expression of fatty acid metabolic genes to promote cardiomyocyte maturation. Finally, intraperitoneal injection of AP-1 inhibitor T-5224 in neonatal mice inhibits cardiomyocyte maturation in vivo.
Conclusion
Our results are the first evidence implicating AP-1 transcription factors in post-natal cardiomyocyte maturation both in vitro and in vivo, which expand our understanding of the molecular mechanism of cardiomyocyte maturation, and may lead to novel therapies to treat congenital heart diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem…
- School of Life Sciences and Technology, Department of Bioinformatics, Tongji University, Shanghai, China.
- Shanghai East Hospital, Key Laboratory of Arrhythmias of the Ministry of Education of China, School of Life Sciences and Technology, Department of Biological Medicine and Biotechnology, Tongji University, Shanghai, Chin…
ORCID-Profile: Hongjie Zhang, Ke Wei
Förderung
- Key Research and Development Program
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Zhang, H., Pei, L., Ouyang, Z., Wang, H., Chen, X., Jiang, K., Huang, S., Jiang, R., Xiang, Y., & Wei, K. (2023). AP-1 activation mediates post-natal cardiomyocyte maturation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac088
Vancouver
Zhang H, Pei L, Ouyang Z, Wang H, Chen X, Jiang K, et al. AP-1 activation mediates post-natal cardiomyocyte maturation. Cardiovascular Research. 2023. doi:10.1093/cvr/cvac088
BibTeX
@article{Zhang2023,
author = {Zhang, Hongjie and Pei, Lijuan and Ouyang, Zhaohui and Wang, Haocun and Chen, Xin and Jiang, Kai and Huang, Shiqi and Jiang, Rui and Xiang, Yaozu and Wei, Ke},
title = {AP-1 activation mediates post-natal cardiomyocyte maturation},
journal = {Cardiovascular Research},
year = {2023},
doi = {10.1093/cvr/cvac088}
}
EUVIMED